Systematic Review

NT-proBNP Concentrations in the Umbilical Cord and Serum of Term Neonates: A Systematic Review and Meta-Analysis

Evangelos Christou 1,2,*,†, Zoe Iliodromiti 1,†, Abraham Pouliakis 3, Rozeta Sokou 1, Matina Zantiotou 4, Chrisa Petropoulou 1, Theodora Boutsikou 1 and Nicoletta Iacovidou 1

1 Neonatal Department, Aretaieio Hospital, National and Kapodistrian University of Athens, 115 28 Athens, Greece; ziliodromiti@yahoo.gr (Z.I.); sokourozeta@yahoo.gr (R.S.); chrisapetra@gmail.com (C.P.); theobtsk@gmail.com (T.B.); niciac58@gmail.com (N.I.)
2 PICU, Fanagiotis and Aglaia Kyriakou Children’s Hospital, 115 27 Athens, Greece
3 2nd Department of Pathology, “ATTIKON” University Hospital, National and Kapodistrian University of Athens, 124 61 Athens, Greece; apou1967@gmail.com
4 Children’s Hospital Agia Sofia, 115 27 Athens, Greece; matina.zantiotou@gmail.com
* Correspondence: va.xristou@gmail.com
† These authors contributed equally to this work.

Abstract: The detection of NT-proBNP levels both in umbilical cord blood (UCB) samples and in serum samples collected from healthy term neonates during the neonatal period. A systematic review of relevant literature in accordance with PRISMA guidelines was conducted. For quality appraisal, the potential risk of bias was assessed using the BIOCRROSS evaluation tool. The random-effects and fixed-effects models were used to calculate weighted mean differences with a corresponding 95% confidence interval. A total of forty (40) studies met the inclusion criteria for the systematic review. After further examination, eighteen (18) studies (1738 participants) from the UCB sample group and fourteen (14) studies (393 participants) from the serum sample group were selected to perform a meta-analysis. Using the fixed-effects model, the mean intervals of NT-proBNP in UCB and serum samples were 492 pg/mL (95% CI: 480–503 pg/mL) and 1341 pg/mL (95% CI: 1286–1397 pg/mL), respectively. A higher concentration of NT-proBNP was observed in the serum sample group compared to the UCB samples (p < 0.001). We present the intervals of NT-proBNP in UCB and in the serum of healthy term neonates. The determination of the potential effect of perinatal factors on the biomarker’s reference range was also aimed.

Keywords: biomarker; neonate; Nt-proBnp; serum; umbilical cord

1. Introduction

Ever since Sudoh [1] discovered a peptide homologous to the ANP peptide isolated from porcine brain tissue in 1988, which subsequently was detected to be produced in the cardiac ventricles, BNP has been extensively studied.

The human BNP gene is located on chromosome 1 and encodes the 108-amino-acid precursor, proBNP. The prohormone is proteolytically processed by the enzyme furin and is cleaved into a biologically active 32-amino-acid peptide (BNP), after being separated from its biologically inert N-terminal fragment (NT-proBNP).

Cardiac myocytes constitute the major source of the neurohormone’s production, whereas cardiac fibroblasts, whose contribution is not yet accurately determined, are also considered responsible for its production. Although the atrium is the main cardiac production site under normal conditions, in the case of chronic myocardial stress, activation of ventricular hormone synthesis occurs. Furthermore, in contrast to ANP, atrial cells provide less storage for BNP, which demonstrates a lower basal production rate. BNP is characterized by an acute response to stress stimuli, in terms of a faster production onset and significantly higher plasma concentrations in patients with heart failure.
Natriuretic peptides are activated and exhibit their full biological activity upon binding to their respective biologically active receptors, namely NPR-A and NPR-B (also known as biologically active guanylyl cyclase receptors) and NPR-C, whose primary function is the clearance of the natriuretic peptides. Since natriuretic peptide receptors are located on most target organs involved in the cardiovascular homeostasis, the physiological effects of BNP are manifold. In the kidney, BNP increases the glomerular filtration rate and inhibits the tubular fractional reabsorption of sodium and water. In the cardiovascular system, it primarily demonstrates an autocrine function by releasing NO, resulting in the decrease in peripheral vascular resistance by relaxing the vascular smooth muscle cells. Moreover, BNP reduces renin secretion and is responsible for the inhibition of thirst, which induces vasodilation, and the decrease in blood volume and arterial pressure. Finally, BNP signaling is crucial for embryonic cardiac stem cell differentiation. It improves myocardial remodeling. The neurohormone is cleared from plasma mainly by binding to the natriuretic peptide receptor type C (NPR-C), which is expressed at high density in the glomerulus of the kidneys and its supportive vascular system. The proteases nephrilysin and meprin-A are considered responsible for the catabolism of the above-mentioned peptides. The half-lives of BNP and NT-proBNP are 20 and 120 s, respectively.

As a biomarker, in the adult population, it has been thoroughly studied, and its clinical applications, mainly in cardiology and endocrinology, are well documented. Normal BNP reference values in healthy adults and reference intervals indicative of various pathological conditions have been determined in large multicenter studies, and therefore, it may be used as a tool for assessing response to treatment [2]. Further research in the pediatric age group is eagerly anticipated. There has been growing interest concerning its clinical utility as a prognostic factor regarding the expected outcome for patients with conditions related to prematurity (HsPDA being a typical example [3], bronchopulmonary dysplasia [4], retinopathy of prematurity [5]), or conditions affecting older children (Kawasaki syndrome [6] and MIS-C [7]); reference intervals, though, for neonates, and children have not yet been established.

The aim of this systematic review and meta-analysis was a literature search of the detection of NT-proBNP levels in healthy full-term neonates at birth using UCB samples and from serum collected during the first month of life (neonatal age). Furthermore, we aimed at determining the potential effect of demographic and perinatal factors on its reference range during this particular period of time.

2. Methods
2.1. Search Strategy

This systematic review followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement [8].

We conducted a systematic review of the literature published as of the year 2000. The study consists exclusively of English-language articles. A scoping review framework that provided a systematic methodology using the electronic databases “Medline”, “Google Scholar”, and “Scopus” was undertaken. Expanded gray literature (including publications that were not reviewed by scientific journals) using appropriate MeSH terms was added to the searches of electronic databases.

2.2. Inclusion and Exclusion Criteria

The objective of this study was the detection of NT-proBNP levels in UCB and in the serum of healthy term newborn infants. Term birth was defined as between 37 and 41 weeks of gestation.

Studies that included preterm neonates (birth at <37 weeks of gestation), or neonates with congenital infections or defects, and papers mentioning neonatal or maternal perinatal morbidity were excluded from this review. Incomplete medical records were also excluded from the analysis. Congress abstracts, theses, dissertations, studies that did not involve human subjects, and papers that failed to meet the definition of original research did
not meet the inclusion criteria of this study. Observational studies that determined UCB and serum NT-proBNP levels in healthy term neonates met the inclusion criteria. The control groups from studies that compared UCB and serum NT-proBNP levels in healthy term neonates and neonates with morbidities (type III fetal heart rate, neonatal stress, IUGR neonates, offsprings of women with type I diabetes, nonimmune hydrops, neonates with congenital heart disease, transient tachypnea of the newborn, respiratory distress syndrome) were also included in this study. 

As far as the serum NT-proBNP values are concerned, the classification into subgroups according to the neonate’s day of life on which they were obtained posed a difficulty, since there was no accordance on the day of the one-month period that the biomarker was measured between the identified studies. In case multiple values were measured, those that included the first day of life were selected, since they represent the majority of the total values. Hence, those obtained on a later day of the neonate’s life were not included in the meta-analysis. 

With regard to the biomarker’s concentration units used in the selected studies (ng/L, fmol/L, pg/mL), all measurements were converted into pg/mL in order to enable statistical data analysis.

2.3. Data Extraction

Literature search and data extraction were independently performed by 2 reviewers (E.C. and Z.I.). The abstracts were thoroughly evaluated for the selection of the appropriate studies. The identified studies were properly tested for eligibility after screening titles and analyzing the abstracts for inclusion and exclusion criteria, resulting in an extensive assessment of existing literature. The full texts of potentially relevant studies were obtained and were evaluated after the authors, the year of publication, the study design, any demographic and perinatal factors involved, the biomarker’s values, and the main findings were taken into account.

2.4. Study Quality

For quality appraisal, the BIOCROSS evaluation tool was applied. BIOCROSS is a new study quality assessment tool, designed specifically to evaluate the reliability of observational studies employing biomarker data [9]. It facilitates a comprehensive review of a biomarker’s reference range that enables the evaluation of normal or abnormal medical conditions. 

The BIOCROSS tool includes ten items divided into five domains: “Study Rationale”, “Design/Methods”, “Data Analysis”, “Data Interpretation”, and “Biomarker Measurement”. Study quality is low for scores less than or equal to 6, moderate between 7 and 12, and high if greater than 13.

2.5. Risk of Bias

Although the BIOCROSS evaluation tool has not been specifically designed to accurately calculate the potential risk of bias, it consists of several subsections that may serve as raters for its indirect estimation. The third item assesses the description of study population characteristics and the confounding factors that may influence the biomarker’s measurements. The fourth and fifth items assess the pertaining methods used to conduct statistical analysis and appraise the quality of the procedure used to measure the biomarker of interest.

2.6. Statistical Analysis

Statistical data processing for the meta-analysis was performed in the R programming software language (version 4.0.4) [10] within the Microsoft Windows environment using the package meta (version 4.18-0) [11,12]. For each parameter under investigation, a forest plot along with the results is presented. A funnel plot was also used to estimate the bias.
Although the selected studies provided little conformity in terms of the presentation of the results, the mean value and the standard deviation were required to conduct meta-analysis on arithmetic data. In cases where this was not possible, an estimation was made by calculating the median and the values of the 1st and 3rd quartiles according to Hozo et al. [13]. Moreover, in case the minimum and maximum values were available, an improved estimation, as proposed by Bland [14], was applied using the Deep Meta Tool, Version 1 [15]. Finally, if the 1st and 3rd quartile values were not available, the range rule was used to estimate the standard deviation value.

In the meta-analysis forest plots, the results are presented using two approaches: (a) the fixed-effects model and (b) the random-effects model. In the fixed-effects model, it is assumed that one phenomenon exists with a specific effect size that all involved studies are estimating. Thus, the weights assigned to studies are based on each one’s sample size, and large studies dominate the analysis results. The random-effects model estimates the mean value of numerous similar phenomena; thus, each study was considered to estimate a different effect size. In this approach, each effect reported by studies is used to calculate a mean effect and a standard deviation. In comparison to the fixed-effects model, in the random-effects model, the weights are more balanced, and large studies do not dominate the results. It is not possible to know if there is a single phenomenon and if it is affected by factors that change across studies (e.g., infant’s age); thus, both approaches are presented.

3. Results

The initial search was performed by analyzing the titles, abstracts, and keywords. A total of one hundred twenty-two (122) papers were retrieved from several bibliographic databases. Further abstract screening yielded seventy-four articles (74), which were found potentially appropriate to be included. After full-text evaluation, thirty-four articles (34) were eliminated, mainly due to a lack of conformity between the identified studies (N = 20) on the specific day of the one-month neonatal period that NT-proBNP levels were measured in serum. Following this, the selected studies underwent eligibility selection, and a number of them were removed from the analysis, primarily due to incomplete medical records as far as the measurement of the biomarker’s levels is concerned (N = 6), cases of non-English-language publications (N = 4) and issues concerning the type of study (abstracts, etc.) (N = 4). A PRISMA flow diagram is presented in Figure 1.

3.1. Participants

The selection process resulted in a final sample of forty (40) studies. A total of twenty-five (25) studies reported NT-proBNP concentrations in UCB samples of term neonates whose mothers did not exhibit any signs of perinatal morbidity. This sample consisted of 2232 term neonates. The rest of the studies, fifteen (15) in total, reported NT-proBNP concentrations in the serum of healthy neonates. This group included 828 neonates. The meta-analysis included eighteen (18) studies concerning UCB samples with 1738 neonates as participants and fourteen (14) studies concerning serum samples collected during the neonatal period with 393 participants.
3.1. Participants

The selection process resulted in a final sample of forty (40) studies. A total of twenty-five (25) studies reported NT-proBNP concentrations in UCB samples of term neonates whose mothers did not exhibit any signs of perinatal morbidity. This sample consisted of 2232 term neonates. The rest of the studies, fifteen (15) in total, reported NT-proBNP concentrations in the serum of healthy neonates. This group included 828 neonates.

The meta-analysis included eighteen (18) studies concerning UCB samples with 1738 neonates as participants and fourteen (14) studies concerning serum samples collected during the neonatal period with 393 participants.

3.2. Umbilical Cord NT-proBNP in Term Neonates

The studies included in the systematic review are presented in Table 1 [16–40].

The NT-proBNP values reported in the selected studies were derived either from the umbilical vein (UV) (nine studies), the umbilical artery (UA) (five studies), or an unspecified umbilical blood sampling vessel (six studies). Regardless of the sampling site and the mode of delivery, NT-proBNP levels were 490 pg/mL on average (95% CI: 479–502 pg/mL) after applying the fixed-weight method and 838 pg/mL (95% CI: 676–999 pg/mL) after applying the random-weight model (shown in Figure 2a). The funnel plot, which is used as a method to assess the potential risk of publication bias is presented in Figure 2b.
Table 1. Characteristics and results of included studies that report on the values of NT-proBNP in umbilical cord of healthy term neonates (N = 25). N/A: not applicable.

| First Author          | Year | Source            | Mode of Delivery | N   | Kit                  | NT-proBNP (pg/mL)               |
|-----------------------|------|-------------------|------------------|-----|----------------------|---------------------------------|
| Won Joon Seong [16]   | 2010 | Umbilical vein    | CS               | 34  | Modular Analytics    | Mean: 801.9 SD: ±537.7          |
|                       |      |                   | VD               | 29  |                      | Mean: 724.3 SD: ±542.4          |
| Leire Cardo [17]      | 2020 | Cord blood        | CS               | 92  | Cobas 6000           | Mean: 662 SD: -                 |
|                       |      |                   | VD               | 177 |                      | Mean: 524 SD: -                 |
| Rafal Kocylowski [18] | 2009 | Umbilical artery  | CS               | 2   | Elecsys 2010         | Mean: 1204 SD: ±1222.6          |
|                       |      |                   | VD               | 154 |                      | Mean: 832 SD: ±253.1            |
| Giuliana Fortunato [19]| 2006| Cord blood        | N/A              | 87  | Elecsys 2010         | Mean: 548.2 SD: -              |
| Anna Girsen [20]      | 2007 | Umbilical artery  | N/A              | 49  | N/A                  | Median: 2630.1 Range: 1319–15814|
| Benjamin Bar-Oz [21]  | 2005 | Cord blood        | N/A              | 122 | Elecsys 2010         | Mean: 578.8 SD: ±351.3          |
| Angelika Lercher [22] | 2005 | Umbilical vein    | N/A              | 42  | Elecsys 2010         | Median: 553.4 SD: -            |
| Jaap Bakker [23]      | 2004 | Cord blood        | N/A              | 71  | Elecsys 2010         | Mean: 668.1 SD: ±363.5          |
| Evelyn Lechner [24]   | 2009 | Cord blood        | N/A              | 200 | Elecsys 2010         | Median: 626 Range: 153–2518     |
| Thomas Mir [25]       | 2003 | Umbilical vein    | VD               | 37  | Biomedica            | Mean: 1691 SD: -                |
| Lynn Schwachtgen [26] | 2005 | Cord blood        | N/A              | 62  | Elecsys 2010         | Mean: 818 SD: ±281–2595         |
| Kübra Irmak [27]      | 2019 | Umbilical vein    | CS               | 43  | CK-E10219            | Mean: 1069 SD: ±721             |
| Sean Martin Fleming [28]| 2001| Umbilical artery  | N/A              | 16  | Biomedica            | Mean: 1885.5 SD: -              |
| Hatem Rouatbi [29]    | 2019 | Cord blood        | N/A              | 169 | Elecsys 2010         | Mean: 296.87 SD: ±273.8         |
| Nicoletta Iacovidou [30]| 2007| Cord blood        | N/A              | 20  | Biomedica            | Mean: 8032.6 SD: -              |
| Karen Halse [31]      | 2005 | Umbilical vein    | N/A              | 22  | N/A                  | Median: 135.2 Range: 76.1–270.6|
| Seung Lee [32]        | 2016 | Umbilical vein    | N/A              | 23  | N/A                  | Median: 633.2 SD: -             |
| Noirin Russell [33]   | 2009 | Cord blood        | N/A              | 39  | Elecsys 2010         | Median: 727.3 Range: 50.7–1403.8|
| Mustafa Mert [34]     | 2015 | Umbilical artery  | N/A              | 58  | ECLI A               | Mean: 592 SD: ±236.8            |
| Anna Girsen [35]      | 2008 | Umbilical artery  | N/A              | 60  | N/A                  | Median: 1649.1 Range: 414.3–3501.1|
Among the selected studies of our systematic review, the biomarker was measured in the UV in ten (10) of them and in the UA in eight (8) of them, while the UCB vessel was not specifically stated in nine (9) of them. A comparison between the biomarker’s levels in UA and UV was approached in only three (3) studies, which concluded that the sampling vessel does not particularly affect the measurements in a statistically significant manner, since only a modest disparity was observed between the two sampling sites, as shown by Kocylowski et al. [18] (UA vs. UV: (mean) 832 pg/mL vs. 831 pg/mL, *p* > 0.001), Bakker et al. [23] (UA vs. UV: (mean) 668 pg/mL vs. 669 pg/mL, *p* > 0.001) and Schwachtgen et al. [26] (UA vs. UV: *p* = 0.652). Contrarily, Blohm et al. [38] described a statistically significant difference between the aforementioned values (UA vs. UV: (median) 765.48 pg/mL vs. 816.45 pg/mL, *p* < 0.001). A meta-analysis was performed by combining data from available studies to produce a comparison between the biomarker’s values according to the chosen UCB vessel, regardless of the mode of delivery (shown in Figure S1). Between the different sampling sites significant heterogeneity was observed when the fixed-weight approach was applied, with lower NT-proBNP levels measured in UV blood—431 pg/mL—(95% CI: 417–446 pg/mL), whereas UA blood NT-proBNP values were 785 pg/mL (95% CI: 754–817 pg/mL) (*p* < 0.0001).

In thirteen (13) studies, a comparison between NT-proBNP levels according to the mode of delivery was attempted. Several of these studies just mentioned this comparison, and the exact values were omitted. Statistically significant increased levels in cesarean section (CS) as opposed to vaginal delivery (VD) were observed in the studies conducted by Kocylowski et al. [18] (CS vs. VD: (median) 630.3 pg/mL vs. 861 pg/mL, *p* > 0.001), Cardo et al. [17] (CS vs. VD: (mean) 662 pg/mL vs. 524 pg/mL, *p* > 0.001), Fortunato et al. [19] (CS vs. VD: (mean) 730 pg/mL vs. 500 pg/mL, *p* < 0.001), in contrast with studies conducted by Won Joon Seong et al. [16] (CS vs. VD: (mean) 801.9 pg/mL vs. 724.3 pg/mL, *p* = 0.572), Bar-Oz et al. [21] (N/A), Bakker et al. [23] (N/A), Schwachtgen et al. [26] (CS vs. VD: *p* = 0.229), Rouati et al. [29] (CS vs. VD: *p* = 0.336), Iacovidou et al. (N/A) [30], Halse et al. [31] (CS vs. VD: *p* = 0.09), Russell et al. [33] (N/A), Girsen et al. [35] (N/A), and Ersoy et al. [40] (*p* = 0.77). Among the articles that provided relevant data, we performed the meta-analysis based on three (3) studies. The NT-proBNP concentration in CS is estimated at 954 pg/mL (95% CI: 826–1082 pg/mL) when the fixed model was applied. Lower levels, i.e., −798 pg/mL—(95% CI: 688–908 pg/mL, *p* = 0.04), were measured in VD (shown in Figure S2), displaying a relatively low heterogeneity rate (I² = 60%) and bias.

| First Author       | Year | Source          | Mode of Delivery | N   | Kit                      | NT-proBNP (pg/mL) |
|--------------------|------|-----------------|------------------|-----|-------------------------|-------------------|
| Mona El-Ganzoury   | 2012 | Umbilical vein  | N/A              | 30  | R & D Systems           | Median: 1310.5    |
|                    |      |                 |                  |     | Vitros 5600             | Range: 870.9–1750.2|
|                    |      |                 |                  |     |                         |                   |
| Alison Lee-Tannock | 2021 | Umbilical vein  | N/A              | 78  | Vitros 5600             | Median: 545       |
|                    |      |                 |                  |     |                         | Range: 368–793    |
|                    |      |                 |                  |     |                         |                   |
| Martin Blohm       | 2019 | Umbilical vein  | N/A              | 86  | Elecsys 2010            | Median: 816.45    |
|                    |      |                 |                  |     |                         | 5th–95th Percentile: 369.62–2233.15 |
|                    |      | Umbilical artery| N/A              | 48  |                         | Median: 765.48    |
|                    |      |                 |                  |     |                         | 5th–95th Percentile: 259.84–1819.5 |
| Martin Blohm       | 2016 | Umbilical vein  | N/A              | 66  | Elecsys 2010            | Mean: 1228.94     |
|                    |      |                 |                  |     |                         | 25th–75th Percentile: 708–1617.5 |
| Ali Ersoy          | 2016 | Umbilical vein  | N/A              | 36  | Elisa kit (USCNK,        | Mean: 1551.18     |
|                    |      |                 |                  |     | Wuhan, Hubei)           | SD: ±1148.9       |

Table 1. Cont.
Figure 2. (a) A forest plot that presents the results of the meta-analysis: umbilical cord NT-proBNP values of term infants using the random model and the fixed model, respectively. The first column refers to the first author of the study, the year of publication, and the sampling vessel. The second column represents the mean value and the standard deviation graph. The next 3 columns show the mean value and the 95% confidence interval. The remaining 2 columns present the fixed model and random model weights [16,18,20,21,23,24,26,27,29,31,33–40]. (b) The corresponding funnel plot is presented at the bottom. (UV: umbilical vein, UA: umbilical artery, CB: cord blood, CS: cesarean section, VD: vaginal delivery).

In seven (7) of the identified studies, a potential correlation between the UCB NT-proBNP levels of term neonates and their mother’s serum NT-proBNP levels prenatally was studied. Specifically, elevated UCB NT-proBNP concentrations in comparison to maternal blood NT-proBNP levels were noted by Bar-oz et al. [21] (UCB NT-proBNP vs. maternal blood NT-proBNP: (mean) 612.2 pg/mL vs. 89.7 pg/mL, $p < 0.001$,
Hammerer-Lercher et al. [22] (UCB NT-proBNP vs. maternal blood NT-proBNP: (median) 553.4 pg/mL vs. 45.5 pg/mL, \( p < 0.001 \)), Bakker et al. (N/A) [23], Lechner et al. [24] (UCB NT-proBNP vs. maternal blood NT-proBNP: (median) 626 pg/mL vs. 66 pg/mL, \( p < 0.001 \)), Iacovidou et al. [30] (\( p = 0.002 \)), Blohm et al. [38] (UV NT-proBNP vs. maternal blood NT-proBNP: (median) 816.45 pg/mL vs. 44.4 pg/mL, \( p < 0.001 \)), and Blohm et al. [39] (UV NT-proBNP vs. maternal blood NT-proBNP: (mean) 1228.94 pg/mL vs. 71.48 pg/mL, \( p = 0.000 \)).

Furthermore, a thorough evaluation of the correlation between the infant’s sex and the biomarker’s UCB concentrations was attempted. No significant sex-dependent correlation was determined among the entire studies included in the review.

### 3.3. Serum NT-proBNP in Term Neonates

The studies that compose the present review are depicted in Table 2 [21,26,41–52].

**Table 2.** Characteristics and results of included studies that report on the values of NT-proBNP in serum of healthy term neonates (N = 15). N/A: NOT applicable.

| First Author        | Year | Age Range   | N  | Kit         | NT-proBNP (pg/mL) |
|---------------------|------|-------------|----|-------------|-------------------|
| Benjamin Bar-Oz [21]| 2005 | Day 1–4     | 33 | Elecsys 2010| Mean: 3042.4      |
|                     |      |             |    |             | SD: ±1783.2       |
| Manfred Rauh [41]   | 2003 | Day 0–12    | 13 | Elecsys 2010| Range: 1121–7740  |
|                     |      |             |    |             | Mean: 1877.1      |
| Thomas Mir [25]     | 2003 | Day 0       | 14 | Biomedica   | Mean: 5419.9      |
|                     |      |             |    |             | SD: ±490.4–6586.8 |
|                     |      | Day 1       | 18 |             | Mean: 2703        |
|                     |      | Day 2       | 12 |             | SD: -             |
|                     |      | Day 3       | 16 |             | Mean: 2064.8      |
|                     |      | Day 4       | 18 |             | SD: -             |
|                     |      | Day 5–7     | 16 |             | Mean: 1724.9      |
|                     |      | Day 8–14    | 10 |             | SD: -             |
|                     |      | Day 15–30   | 12 |             | Mean: 1437.4      |
| Amiram Nir [42]     | 2004 | Day 1–5     | 20 | Elecsys 2010| Mean: 1937        |
|                     |      |             |    |             | SD: ±328          |
| Steven Soldin [43]  | 2006 | Day 0–30    | 99 | Dade R XL   | 97th: 31832.5     |
| Lynn Schwachtgen [26]| 2005 | Day 0–1     | 8  | Elecsys 2010| Mean: 6072        |
|                     |      |             |    |             | SD: ±546          |
|                     |      | Day 2–3     | 40 |             | Mean: 2972        |
|                     |      | Day 4–8     | 11 |             | SD: ±1808         |
| Chiara Caselli [44] | 2016 | Day 0–30    | 24 | Elecsys 2010| Mean: 1731        |
|                     |      |             |    |             | SD: ±1236         |
| Amiram Nir [45]     | 2009 | Day 0–2     | 43 | Elecsys 2010| Median: 3183      |
|                     |      |             |    |             | Range: 260–13,224 |
|                     |      | Day 3–11    | 84 |             | Median: 2210      |
|                     |      |             |    |             | Range: 28–7.250   |
Table 2. Cont.

| First Author       | Year | Age Range   | N  | Kit          | NT-proBNP (pg/mL)                          |
|--------------------|------|-------------|----|--------------|-------------------------------------------|
|                    |      |             |    |              | Median: 1360                               |
|                    |      |             |    |              | Range: 250–3987                            |
| Sai Li [46]        | 2018 | Day 0–30    | 80 | VIDAS        | Mean: 398                                 |
|                    |      |             |    |              | SD: ±425                                  |
| Kambiz Norozi [47] | 2009 | Day 0–30    | 8  | Elecsys 2010 | Median: 1388.5                             |
|                    |      |             |    |              | Range: 750–4615                            |
|                    |      |             |    |              | Median = 640.8                             |
|                    |      |             |    |              | Range 515–850                             |
| Menghong Deng [48] | 2016 | Day 0–4     | N/A| YZB/CAN 1794-2008 | Median = 412.7                             |
|                    |      |             |    |              | Range 341–462                             |
|                    |      | Day 5–15    | N/A|              | Median: 1491                              |
|                    |      | Day 16–28   | N/A|              | Percentiles 5th–95th: 499.5–8607.3         |
| Rui Zhu [49]       | 2015 | Day 0–3     | 63 | Elecsys 2010 | Median: 3509                              |
|                    |      |             |    |              | Min–Max: 1174–35,000                       |
|                    |      |             |    |              | Median: 3517                              |
|                    |      |             |    |              | Min–Max: 875–16,452                        |
|                    |      |             |    |              | Median: 1211                              |
|                    |      |             |    |              | Min–Max: 377–2774                          |
|                    |      |             |    |              | Median: 808                               |
|                    |      |             |    |              | Min–Max: 440–2284                          |
| Ozger Aydemir [50] | 2012 | 6th hour of life | 33 | Immulite 2000 | Median: 8070                               |
|                    |      |             |    |              | SD: ±1020                                 |
|                    |      |             |    |              | Mean: 3509                                |
|                    |      |             |    |              | Min–Max: 1174–35,000                       |
|                    |      |             |    |              | Median: 3517                              |
|                    |      |             |    |              | Min–Max: 875–16,452                        |
|                    |      |             |    |              | Median: 1211                              |
|                    |      |             |    |              | Min–Max: 377–2774                          |
|                    |      |             |    |              | Median: 808                               |
|                    |      |             |    |              | Min–Max: 440–2284                          |
| Azza Ahmed [51]    | 2020 | Day 0–30    | 26 | Abnova       | Mean: 8210                                 |
|                    |      |             |    |              | Range: 6.110–10.460                        |
| Gordana Marcovic [52] | 2014 | Day 1–28   | 28 | Elecsys 2010 | Median: 8070                               |

The identified studies displayed little accordance on a specific day, through the 30-day neonatal period, that the biomarker’s serum levels were measured. In case multiple values on separate days were available, those that included the first or second day of life were selected, since they represent the majority of the total values. Statistical data from fourteen (14) studies were available for processing. The forest plot is depicted in Figure 3a. According to the fixed-effects model, the NT-proBNP serum levels were 1341 pg/mL (95% CI: 1286–1397 pg/mL), while the random-effects model showed an almost 3-fold elevation of levels at 3176 pg/mL (95% CI: 2049–4303 pg/mL). The associated funnel plot (shown in Figure 3b) is indicative of the high bias rate that characterizes the studies. The comparison between cumulative NT-proBNP values in serum and UCB demonstrates a relatively higher serum concentration ($p < 0.0001$).

Another observation is that NT-proBNP levels gradually decrease as the ages of the neonate’s advance. Several studies have reported a negative correlation between NT-proBNP values and age such as the studies of Rauh et al. [41] ($r = −0.45, p < 0.001$), Li et al. [46] ($r = −0.23, p < 0.05$), and Deng et al. [48] ($r = −0.706, p = 0.000$). Nir et al. [42] reported significantly higher levels of the biomarker during the neonate’s first days of life as opposed to later days ($p < 0.05$), while infants between 4 months and 15 years old did not exhibit a remarkably wide range of values (regression analysis, $r^2 = 0.18$). Soldin et al. study [43] reported that during the neonatal period, NT-proBNP levels were elevated up to 20 times in comparison to infancy, even though the study population was limited in size. Additionally, NT-proBNP levels slowly decrease and gradually approach the adult reference range, as demonstrated in the studies of Rauh et al. [41], Koch et al. [53], and Deng et al. [48]. Schwachtgen et al. [26], on the other hand, observed a rapid NT-proBNP increase during the first 2 days of life, when compared to their respective UCB levels, which is succeeded by a rapid decrease during the first year of life, that persists until normal values are achieved approximately at early adulthood. Similar results appeared in the studies of Caselli et al. [44] and Zhu et al. [49]. Markovic-Sovtic et al. [52] claimed that elevated values are measured during the 1st week of life in comparison to those obtained
during the rest of the 1st month ($p < 0.001$). In contrast to the aforementioned studies, Mir et al. [54] reported no statistically significant difference according to the infant’s day of life as far as the biomarker’s concentration is concerned. None of the elected studies proved that the biomarker’s values are affected by the infant’s sex, as shown in the following studies.

None of the elected studies proved that the biomarker’s values are affected by the infant’s sex, as shown in the following studies.

| Study                        | Mean       | MRAW       | 95%-CI    | Weight (fixed) | Weight (random) |
|------------------------------|------------|------------|-----------|----------------|-----------------|
| Bar-Oz et al. 2005           | 3042       | [2434; 3651]| 0.8%      | 7.2%           |                 |
| Rauh et al. 2003             | 3310       | [2410; 4209]| 0.4%      | 7.0%           |                 |
| Mir et al. (day 0) 2003      | 1877       | [278; 3477]| 0.1%      | 6.4%           |                 |
| Nir et al. 2004              | 1937       | [1793; 2081]| 15.1%     | 7.3%           |                 |
| Schwachtgen et. al. (day 0-1) 2005 | 6072   | [5694; 6450]| 2.2%      | 7.3%           |                 |
| Caselli et al. 2016          | 541        | [467; 614] | 58.2%     | 7.3%           |                 |
| Nir et al. (day 0-2) 2009    | 3183       | [2214; 4152]| 0.3%      | 7.0%           |                 |
| Sai Li et al. 2018           | 1360       | [1155; 1565]| 7.4%      | 7.3%           |                 |
| Norozi et al. 2009           | 398        | [103; 693] | 3.6%      | 7.3%           |                 |
| Deng et. al. (day 0-4) 2016  | 1388       | [1170; 1607]| 6.5%      | 7.3%           |                 |
| Zhu et. al. 2015             | 1491       | [990; 1992]| 1.2%      | 7.2%           |                 |
| Aydemir et. al. (day 1) 2012 | 3517       | [2188; 4846]| 0.2%      | 6.7%           |                 |
| Azza et. al. 2020            | 8070       | [7678; 8462]| 2.0%      | 7.3%           |                 |
| Markovic-Sovic et. al. 2014  | 8210       | [7807; 8613]| 1.9%      | 7.3%           |                 |

**Fixed effect model**

**Random effects model**

Heterogeneity: $I^2 = 100\%$, $t^2 = 4496289.7$

|                | MRAW       | 95%-CI    | Weight (fixed) | Weight (random) |
|----------------|------------|-----------|----------------|-----------------|
|                | 1341       | [1286; 1397]| 100.0%        |                 |
|                | 3176       | [2049; 4303]| 100.0%        |                 |

Figure 3. (a) A forest plot that presents the meta-analysis of the NT-proBNP values of healthy term neonates during the neonatal period, after the application of the random or the fixed model. The first column refers to the first author, the year of publication, and the day of neonates’ life on which the measurement occurred (in parentheses). The second column represents the mean value and the standard deviation graph. The next 3 columns show the mean value and the 95% confidence interval. The remaining 2 columns present the fixed model and random model weights [21,25,26,41,42,44–52].

(b) A funnel plot that presents the meta-analysis of NT-proBNP values in healthy term neonates at the bottom.

3.4. Quality of Studies

As far as studies about the UCB NT-proBNP concentration are concerned, four (4) out of twenty-five (25) were characterized as of “low quality”, twenty (20) of moderate quality, and one (1) met the criteria of the high-quality study, according to the BIOCROSS evaluation tool (shown in Figure 4a).
Figure 4. (a) Biocross evaluation tool for the assessment of the umbilical cord studies [16–40]. (b) Biocross evaluation tool for the assessment of the serum studies [21,25,26,41–52].

Articles that obtained low scores displayed underlying errors or defects particularly concerning the description of exclusion criteria, specimen characteristics, assay methods,
laboratory measurements, and biomarker modeling. Specifically, only nine (9) out of the twenty-two (22) studies mentioned the quality control procedures of biomarker measurement (e.g., inter- and intra-coefficient of variation). There are important limitations concerning the reproducibility assessment performed for evaluating the biomarker’s stability (2/22), as well as the citation of potential technical errors in measurements (0/22). On the contrary, the effect of potential confounding factors was relatively well established, since only two (2) of the studies presented a lack of such assessment.

As far as the fifteen (15) studies that referred to serum NT-proBNP levels of healthy term neonates during the neonatal period are concerned, five (5) of them were of low quality, and the rest were characterized as of moderate quality (shown in Figure 4b). Studies on the biomarker’s UCB levels display similar limitations.

4. Discussion

The present systematic review and meta-analysis aimed at studying the UCB and serum NT-proBNP levels in healthy term neonates during their first month of life.

As embryonic development progresses, BNP follows a different metabolic pathway in comparison to ANP, whose UV levels appear elevated when compared to those that derive from the UA, implying a potential endogenous placental production, accounting for a role in fetoplacental hemodynamics [55]. On the contrary, BNP, and consequently, NT-proBNP concentrations, do not display a decrease after passing through the placenta, attributable to a lower NPR-C receptor affinity and a higher neutral endopeptidase affinity [56, 57]. Moreover, it appears that the secretion of NT-proBNP detected in the amniotic fluid derives primarily from embryonic cardiomyocytes [55, 58]. Suga et al. [57] and Carvajal et al. [59], however, suggested that it derives from the amniotic fluid, mediated by paracrine mechanisms of myometrial cells, before ultimately entering the fetal circulation. NT-proBNP levels are significantly elevated in healthy pregnancies until mid-pregnancy and tend to reach a plateau at around 34 weeks of gestation. Specifically, the study of Merz et al. [58] reported that the mean NT-proBNP concentration is 1998 pg/mL between 20 and 34 weeks of gestation, while the Carvajal et al. [60] study calculated the same concentration to be at 1782 pg/mL.

Blohm et al. [38] reported that UCB and amniotic fluid levels of the biomarker at birth do not exhibit a remarkable correlation (amniotic fluid NT-proBNP vs. UV NT-proBNP: (mean) 816.45 pg/mL vs. 72.03 pg/mL, \( p < 0.01 \)), which was also supported by the study of Esroy et al. [40] (Spearman’s \( r = 0.2, p = 0.07 \)), and results from the crucial hemodynamic changes that occur during the transition from intrauterine to extraterine life. The study of Miyoshi et al. [61], however, proved a relatively weak, yet statistically significant, correlation between UCB and amniotic fluid values of the biomarker at birth (Spearman’s \( r = 0.51, p < 0.01 \)), notwithstanding the detection of 22-fold higher UV NT-proBNP levels compared to the respective amniotic fluid levels.

Although there has been growing interest concerning the clinical utility of NT-proBNP as a prognostic and diagnostic tool regarding neonatal morbidity, a robust assessment of the levels expected in neonates is yet to be performed, since it is an essential prerequisite in clinical practice. In the present meta-analysis, the mean value of NT-proBNP was calculated at 490 pg/mL (95% CI: 479–502 pg/mL) using the fixed-effects model and at 838 pg/mL (95% CI: 676–999 pg/mL) according to the random-effects model. Significant heterogeneity was documented among the selected studies, since they referred to study populations with distinct racial characteristics, they presented low representativeness that could be attributed to specific study design requirements, and they had a limited size population. No detectable difference in values was observed with the mode of delivery, the infant’s sex, or the UCB vessel.

A few studies undertook a comparison between the biomarker’s levels according to the UCB sampling vessel. No statistically significant difference was reported in three (3) of them [18, 23, 26], as opposed to the study of Blohm et al. [38], which detected elevated UV NT-proBNP values in comparison to the respective UA values. The present meta-
analysis, which includes data from twelve (12) studies, depicts a minor yet statistically significant difference in favor of the UA, in comparison to the UV sampling site, according to the fixed-effects model (431 pg/mL, 95% CI: 417–446 pg/mL vs. 785 pg/mL, 95% CI: 754–817 pg/mL, p < 0.001).

Concerning the mode of delivery, elevated NT-proBNP levels were noted in the case of CS in comparison to VD in three (3) of the selected studies [17–19], whereas a total of ten (10) studies observed no such difference [16,21,23,26,29–31,33,35,40]. Our meta-analysis (which included three (3) studies that met the inclusion criteria) is consistent with the findings of the first group of researchers, since we concluded that the values measured were slightly elevated in the case of CS (CS vs. VD: 954 pg/mL (95% CI: 826–1082 pg/mL) vs. 798 pg/mL, (95% CI: 688–908 pg/mL, p < 0.001). The limited number of studies that met the inclusion criteria accounts for the relatively poor reliability of the aforementioned result. It is safe to assume that no significant correlation actually exists between CS, mode of delivery, and high levels of neonatal stress or cardiac overload, which are considered responsible for the increased production of NT-proBNP at birth. A noteworthy fact is that a remarkable difference is observed neither in the case of emergency CS, nor in the case of emergency spontaneous VD [19,31], which denotes that delivery constitutes a considerably stressful procedure for the fetus, and consequently, NT-proBNP levels fail to serve as an independent discriminant biomarker of stress [29].

None of the selected studies proved that the biomarker’s values are affected by the infant’s sex. This remains the case until late childhood, since in adolescence, the substantially higher levels of NT-proBNP in female subjects can be attributed to the inverse regulatory association between testosterone and NT-proBNP, suggesting that androgens modulate sex differences notable in the secretion of natriuretic peptides (NPs) [62,63].

A remarkable discrepancy was confirmed between NT-proBNP concentrations that derive from UCB and maternal serum samples during labor. More specifically, five (5) studies that attempted a comparison [21,22,24,38,39] provided the observation that NT-proBNP UCB values presented a 15-fold increase according to the fixed model method (95% CI: 14–16, p < 0.01) (shown in Figure S3). NT-proBNP’s production, secretion, and clearance of NPs are regulated independently in the neonatal and maternal circulation.

As described in the present meta-analysis, the serum NT-proBNP levels in healthy term infants during the neonatal period were 1341 pg/mL (95% CI: 1286–1397 pg/mL) and 3176 pg/mL (95% CI: 2049–4303 pg/mL) according to the fixed-effects model and the random-effects model, respectively. High levels of heterogeneity across studies were also identified in this case. Higher serum NT-proBNP levels are observed in comparison to UCB NT-proBNP levels during the neonatal period (p < 0.0001). This scientific obstacle, which is confirmed in literature references [21,22,25,26,50,64], derives from multiple pathophysiological mechanisms, such as the placenta influence on BNP clearance [64], the newborn’s water loss increase postnatally, the renal function immaturity [65], and the significant changes that occur due to the gradual functional closure of ductus venosus, foramen ovale, and ductus arteriosus during the first hours of life of term neonates [66].

The postnatal profound hemodynamic changes and, specifically, the pulmonary perfusion and the systemic afterload increase are responsible for the high right ventricular cardiac volume and cardiac output, which leads to a BNP gene expression stimulation. The procedure is mainly mediated by mitogen-activated protein kinases and, specifically, the extracellular signal-regulated kinase, which is activated as a response to the stimulus of pressure overload on the cardiac myocytes [67]. Consequently, the NT-proBNP concentration is relatively high in the first week and then gradually decreases significantly. The decrease in plasma NT-proBNP can be attributed to the diuresis that goes along with renal maturation, the suppression of renin-aldosterone-angiotensin I and II system activity, and the neonate’s water loss increase postnatally [68]. The gradual serum level decrease in the biomarker continues until the first months of life and remains considerably stable from infancy to the beginning of adolescence [25,26,41,43–49,52,54,69].
A number of practical scientific obstacles were encountered throughout the process of conducting the present systematic review and meta-analysis; thus, several important limitations are mentioned hereby. To begin with, employing the cross-sectional survey design results in obvious study limitations. Then, vascular punctures in healthy newborns, especially if performed without indication, are associated with higher levels of neonatal stress and perinatal morbidity [70]. Therefore, there has been a tendency to avoid any purposeless invasive procedures performed in neonates during the past decades, which in turn causes difficulties in conducting studies that aim to establish intervals for the biomarker levels in blood samples of healthy neonates, since the majority only include NT-proBNP values that refer to neonates with morbidities. Third, various clinical laboratory NT-proBNP measurement methods are reported. The different kinds of immunoassays lack necessary standardization, and the results that derive from different kits are not sufficiently comparable [71]. The inter-assay discrepancy may also be attributed to the heterogeneity of antibodies that are used to detect different NT-proBNP fragments, as well as the fact that little conformity exists between different analyzer kit labels concerning the technical characteristics of the in vitro determination of the biomarker’s concentrations [72,73]. This could probably provide an explanation for the high levels of heterogeneity that were observed among the selected studies. Nevertheless, in order to ensure satisfactory reliability, a large number of studies have been examined. Moreover, several studies were considered to be of low quality according to the BIOCROSS evaluation tool, which results in a potential publication bias. Large multicenter studies in populations of healthy term neonates with distinct demographic characteristics are required in order to determine intervals for NT-proBNP by analyzing UCB and serum samples during the neonatal period. Last, further investigation on the potential effect of perinatal and demographic factors on the biomarker’s range is undoubtedly necessary.

5. Conclusions

The current study pioneers in analyzing and introducing reliable intervals for NT-proBNP in UCB and healthy term neonates’ serum during the neonatal period. Furthermore, an identification of presumable correlations between the biomarker’s levels and certain variables of the perinatal period or neonatal demographic characteristics was accomplished. It is common knowledge that infant reference intervals are rather difficult to address in modern healthcare, since access to blood samples from healthy neonates is limited by ethical and practical constraints. The conduction of reliable large-scale studies with a representative sample of participants is greatly anticipated in an attempt to establish accurate reference intervals specific to the neonatal population.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/diagnostics12061416/s1, Figure S1: A forest plot that depicts the discrepancy of NT-proBNP concentrations depending on the sampling vessel being the umbilical vein or the umbilical artery, applying the random model or the fixed model. The first column states the first author and the year of publication. The second column represents the mean value and the standard deviation graph. The next three columns show the mean value and the 95%. The remaining two columns present the fixed model and random model weights. The corresponding funnel plot is presented at the bottom. (UV: Umbilical vein, UA: Umbilical artery, CS: Cesarean section, VD: Vaginal delivery) Figure S2: A forest plot that shows the variance of NT-proBNP values according to the mode of delivery, using the random or the fixed model. The first column states the first author and the year of publication. The second column represents the mean value and the standard deviation graph. The next 3 columns show the mean value and the 95%. The remaining 2 columns present the fixed model and random model weights. The corresponding funnel plot is presented at the bottom. (UV: Umbilical vein, CS: Cesarean section, VD: Vaginal delivery) Figure S3: A forest plot that shows the difference between the maternal and umbilical NT-proBNP at birth applying the random model or the fixed model. The corresponding funnel plot is presented at the bottom.

Author Contributions: E.C. and Z.I. conceptualized and designed the study, drafted the initial manuscript, and reviewed and revised the manuscript. A.P. designed the data collection and carried
out the initial analyses. R.S., M.Z. and C.P. coordinated and supervised data collection, and critically reviewed the manuscript for intellectual content. T.B. and N.I. reviewed and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** All data generated or analyzed during this study are included in this article and its supplementary material files. Further inquiries can be directed to the corresponding author.

**Conflicts of Interest:** The authors declare that they have no conflict of interest.

**Abbreviations**

Cesarean section (CS), natriuretic peptides (NPs), umbilical cord blood (UCB), umbilical artery (UA), umbilical vein (UV), vaginal delivery (VD).

**References**

1. Sudoh, T.; Kangawa, K.; Minamino, N.; Matsuo, H. A new natriuretic peptide in porcine brain. *Nature* **1988**, *332*, 78–81. [CrossRef] [PubMed]
2. Gupta, K.; Wang, J. Natriuretic Peptides and Cardiometabolic Health. *Circ. J.* **2015**, *79*, 1647–1655. [CrossRef] [PubMed]
3. Rodriguez-Blanco, S.; Oulegro-Errroz, I.; Gautreaux-Minaya, S.; Perez-Muñuzuri, A.; Luz Couce-Pico, G.; Boutsikou, T.; Iacovidou, N. Serum and Urinary N-Terminal Pro-brain Natriuretic Peptides as Biomarkers for Bronchopulmonary Dysplasia of Preterm Neonates. *Front. Pediatr.* **2020**, *8*, 588738. [CrossRef]
4. Bührer, C.; Erdeve, Ö.; Van Kaam, A.; Berger, A.; Lechner, E.; Bar-Oz, B.; Allegaert, K.; Stiris, T.; Çelik, İ.H.; Berrington, J. N-terminal B-type natriuretic peptide urinary concentrations and retinopathy of prematurity. *Pediatr. Res.* **2017**, *82*, 958–963. [CrossRef]
5. Dionne, A.; Dahdah, N. A Decade of NT-proBNP in Acute Kawasaki Disease, from Physiological Response to Clinical Relevance. *Children* **2018**, *5*, 141. [CrossRef]
6. Zhao, Y.; Patel, J.; Huang, Y.; Yin, L.; Tang, L. Cardiac markers of multisystem inflammatory syndrome in children (MIS-C) in COVID-19 patients: A meta-analysis. *Am. J. Emerg. Med.* 2021, 49, 62–70. [CrossRef]
7. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ* 2021, 372, n71. [CrossRef]
8. Wirsching, J.; Graßmann, S.; Eichelmann, F.; Harms, L.M.; Schenk, M.; Barth, E.; Berndzen, A.; Olalekan, M.; Sarmini, L.; Zuberer, H.; et al. Development and reliability assessment of a new quality appraisal tool for cross-sectional studies using biomarker data (BIOCROSS). *BMC Med. Res. Methodol.* 2018, *18*, 122. [CrossRef]
9. R Foundation. The R Project for Statistical Computing. 2021. Available online: https://www.rproject.org/ (accessed on 15 January 2022).
10. Schwarzer, G. Meta: An R package for meta-analysis. *R News* **2007**, *7*, 40–45.
11. Blanduzi, S.; Rücker, G.; Schwarzer, G. How to perform a meta-analysis with R: A practical tutorial. *Evid. Based Ment. Health* **2019**, *22*, 153–160. [CrossRef]
12. Hozo, S.P.; Djulbegovic, B.; Hozo, I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med. Res. Methodol.* 2005, *5*, 13. [CrossRef]
13. Bland, M. Estimating Mean and Standard Deviation from the Sample Size, Three Quartiles, Minimum, and Maximum. *Int. J. Stat. Med. Res.* 2014, *4*, 57–64. [CrossRef]
14. Deepanshu, S.; Surya, U.; Vinay, S.; Sakshi, P.; Ravi, R.K.N. Deep Meta Tool: GUI Tool to Obtain Mean and Standard Deviation (SD) from Median and Interquartile Range (IQR). Research Square 2021. Available online: https://www.researchsquare.com/article/rs-828102/v1 (accessed on 20 January 2022).
15. Seong, W.J.; Yoon, D.H.; Chong, G.O.; Hong, D.G.; Koo, T.B.; Lee, T.H.; Chun, S.S. Umbilical cord blood amino-terminal pro-brain natriuretic peptide levels according to the mode of delivery. *Arch. Gynecol. Obstet.* **2010**, *281*, 907–912. [CrossRef]
18. Kocylowski, R.D.; Dubiel, M.; Gudmundsson, S.; Sieg, I.; Fritzner, E.; Akas, O.; Breborowicz, G.H.; von Kaisenberg, C.S. Biochemical tissue-specific injury markers of the heart and brain in postpartum cord blood. *Am. J. Obstet. Gynecol.* 2009, 200, e1–e273. [CrossRef]

19. Fortunato, G.; Carandente Giarrusso, P.; Martinelli, P.; Sglavo, G.; Vassallo, M.; Tomeo, L.; Rea, M.; Paladini, D. Cardiac troponin T and amino-terminal pro-natriuretic peptide concentrations in fetuses in the second trimester and in healthy neonates. *Clin. Chem. Lab. Med.* 2006, 44, 834–836. [CrossRef]

20. Girsen, A.; Ala-Kopsala, M.; Mäkikallio, K.; Vuolteenaho, O.; Räsänen, J. Cardiovascular hemodynamics and umbilical artery N-terminal peptide of pro-B-type natriuretic peptide in human fetuses with growth restriction. *Ultrasound Obstet. Gynecol.* 2007, 29, 296–303. [CrossRef]

21. Bar-Oz, B.; Lev-Sagie, A.; Arad, I.; Salpeter, L.; Nir, A. N-terminal pro-B-type natriuretic peptide concentrations in mothers just before delivery, in cord blood, and in newborns. *Clin. Chem.* 2005, 51, 926–927. [CrossRef]

22. Hammerer-Lercher, A.; Main, J.; Tews, G.; Puschendorf, B.; Sommer, R. N-terminal pro-B-type natriuretic peptide concentrations are markedly higher in umbilical cord blood of newborns than in their mothers. *Clin. Chem.* 2005, 51, 913–915. [CrossRef]

23. Bakker, J.; Gies, I.; Slavenburg, B.; Bekers, O.; Delhaas, T.; Van Dieijen-Visser, M. Reference values for N-terminal pro-B-type natriuretic peptide in umbilical cord blood. *Clin. Chem.* 2004, 50, 2465. [CrossRef] [PubMed]

24. Lechner, E.; Wiesinger-Eidenberger, G.; Wagner, O.; Weissensteiner, M.; Schreier-Lechner, E.; Leibetseder, D.; Arzt, W.; Tulzer, G. Amino terminal pro B-type natriuretic peptide levels are elevated in the cord blood of neonates with congenital heart defect. *Pediatr. Res.* 2009, 66, 466–469. [CrossRef] [PubMed]

25. Mir, T.; Saug, R.; Hellwege, H.H.; Liedke, B.; Heinze, C.; von Buelow, H.; Lärer, S.; Weil, J. Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: Marked and rapid increase after birth. *Pediatrics* 2003, 112, 896–899. [CrossRef] [PubMed]

26. Schwachtgen, L.; Herrmann, M.; Georg, T.; Schwarz, F.; Marx, N.; Lindinger, A. Reference values of NT-proBNP serum concentrations in the umbilical cord blood and in healthy neonates and children. *Z. Kardiol.* 2005, 94, 399–404. [CrossRef]

27. Irmak, K.; Tüten, N.; Karaoglu, G.; Madazli, R.; Tüten, A.; Malik, E.; Gülarp, O. Evaluation of cord blood creatine kinase (CK), cardiac troponin T (cTnT), N-terminal-pro-B-type natriuretic peptide (NT-proBNP), and s100B levels in nonreassuring foetal heart rate. *J. Matern. Fetal Neonatal Med.* 2021, 34, 1249–1254. [CrossRef]

28. Fleming, S.; O’Gorman, T.; O’Byrne, L.; Grimes, H.; Daly, K.M.; Morrison, J.J. Cardiac Troponin I and N-Terminal Pro-Brain Natriuretic Peptide in Umbilical Artery Blood in Relation to Fetal Heart Rate Abnormalities during Labor. *Pediatr. Cardiol.* 2001, 22, 393–396. [CrossRef]

29. Rouatbi, H.; Zizaga, S.; Gkiougki, E.; Vranken, L.; Van Linthout, C.; Seghaye, M.C. Biomarkers of neonatal stress assessment: A prospective study. *Early Hum. Dev.* 2019, 137, 104826. [CrossRef] [PubMed]

30. Iacovidou, N.; Briana, D.D.; Sglavo, G.; Vassallo, M.; Tomeo, L.; Rea, M.; Paladini, D. Cardiac troponin T and amino-terminal pro-natriuretic peptide concentrations in fetuses in the second trimester and in healthy neonates. *Clin. Chem. Lab. Med.* 2006, 44, 834–836. [CrossRef]

31. Lee, S.M.; Jun, J.K.; Kim, S.A.; Kang, M.J.; Song, S.H.; Lee, J.; Park, C.; Park, J.S. N-terminal pro-B-type natriuretic peptide in infants of women with type 1 diabetes. *Hypertens Pregnancy* 2019, 38, 200–206. [CrossRef]

32. Lee, S.M.; Jun, J.K.; Kim, S.A.; Kang, M.J.; Song, S.H.; Lee, J.; Park, C.; Park, J.S. N-terminal pro-B-type natriuretic peptide in infants of women with type 1 diabetes. *Hypertens Pregnancy* 2019, 38, 200–206. [CrossRef]

33. Lee-Tannock, A.; Hay, K.; Kumar, S. Differences in biomarkers of cardiac dysfunction in cord blood between normal pregnancies and pregnancies complicated by maternal diabetes. *Aust. N. Z. J. Obstet. Gynaecol.* 2012, 5, 2. [CrossRef]

34. Blohm, M.; Arndt, F.; Fröschle, G.M.; Langenbach, N.; Sandig, J.; Vettorazzi, E.; Mir, T.S.; Hecher, K.; Weil, J.; Kozlik-Feldmann, R.; et al. Cardiovascular Biomarkers in Amniotic Fluid, Umbilical Arterial Blood, Umbilical Venous Blood, and Maternal Blood at Delivery, and Their Reference Values for Full-Term, Singleton, Cesarean Deliveries. *Front. Pediatr.* 2019, 7, 271. [CrossRef]

35. Blohm, M.E.; Arndt, F.; Sandig, J.; Diehl, W.; Zeller, T.; Mueller, G.C.; Schlesner, C.; Mir, T.S.; Blankenberg, S.; Hecher, K.; et al. Cardiovascular biomarkers in paired maternal and umbilical cord blood samples at term and near term delivery. *Early Hum. Dev.* 2016, 94, 7–12. [CrossRef]

36. Ersoy, A.O.; Ozler, S.; Oztas, E.; Ersoy, E.; Ergin, M.; Erkaya, S.; Uygur, D. The Association between N-terminal Pro-Brain Natriuretic Peptide Levels in the Umbilical Vein and Aminoterminal Fluid Volume Abnormalities. *Rev. Bras. Ginecol. Obstet.* 2016, 38, 177–182. [CrossRef]
41. Rauh, M.; Koch, A. Plasma N-terminal pro-B-type natriuretic peptide concentrations in a control population of infants and children. *Clin. Chem.* 2003, 49, 1563–1564. [CrossRef]

42. Nir, A.; Bar-Oz, B.; Perles, Z.; Brooks, R.; Korach, A.; Rein, A.J. N-terminal pro-B-type natriuretic peptide: Reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. *Acta Paediatr.* 2004, 93, 603–607. [CrossRef]

43. Caselli, C.; Ragusa, R.; Prontera, C.; Cabiati, M.; Cantinotti, M.; Federico, G.; Del Ry, S.; Trivella, M.G.; Clerico, A. Distribution of circulating cardiac biomarkers in healthy children: From birth through adulthood. *Biomark. Med.* 2016, 10, 357–365. [CrossRef] [PubMed]

44. Nir, A.; Lindinger, A.; Rauh, M.; Bar-Oz, B.; Laer, S.; Schwachtgen, L.; Koch, A.; Falkenberg, J.; Mir, T.S. NT-pro-B-type natriuretic peptide in infants and children: Reference values based on combined data from four studies. *Pediatr. Cardiol.* 2009, 30, 3–8. [CrossRef] [PubMed]

45. Li, S.; Xiao, Z.; Li, L.; Hu, B.; Zhou, Z.; Yi, S.; Luo, J.; Xie, L.; Nie, B.; Mo, L.; et al. Establishment of normal reference values of NT-proBNP and its application in diagnosing acute heart failure in children with severe hand foot and mouth disease. *Medicine (Baltimore)* 2018, 97, e12218. Erratum in *Medicine* 2020, 99, e19688. [CrossRef]

46. Norozi, K.; Binder, L.; Brack, C.; Poithoff, L.; Hess, G.; Wessel, A. Intravenous luteinizing hormone-releasing hormone has no effect on serum N-terminal pro-brain natriuretic peptide in children and adolescents. *Pediatr. Int.* 2009, 51, 283–288. [CrossRef]

47. Suga, S.; Nakao, K.; Hosoda, K.; Mukoyama, M.; Ogawa, Y.; Shirakami, G.; Arai, H.; Saito, Y.; Kambayashi, Y.; Inouye, K.; et al. Amniotic Fluid Natriuretic Peptide Levels in Fetuses with Congenital Heart Defects or Arrhythmias. *BJOG 2004*, 111, 452–455. [CrossRef]

48. Koch, L.; Dabeck, M.T.; Frommhold, D.; Poeschl, J. Stable precursor fragments of vasoactive peptides in umbilical cord blood of term and preterm infants. *Horm. Res. Paediatr.* 2011, 76, 234–239. [CrossRef] [PubMed]

49. Merz, W.M.; Leufgen, C.; Fimmers, R.; Stoffel-Wagner, B.; Gemburc, U. Reference intervals for N-terminal pro-brain natriuretic peptide in amniotic fluid between 10 and 34 weeks of gestation. *Early Hum. Dev.* 2012, 88, 315–319. [CrossRef] [PubMed]

50. Ahmed, A.M.; Mohamed, N.A.E.; Abdelhamid, E.M.; Taha, R.I.; Abo-Hashish, M.M.A. N-terminal pro-brain natriuretic peptide as a biomarker for differentiating cardiac and pulmonary disease in term neonates with respiratory distress. *J. Saudi Heart Assoc.* 2020, 32, 65–70. [CrossRef]

51. Markovic-Sovtic, G.; Kosutic, J.; Jankovic, B.; Bojanin, D.; Sovtic, A.; Rakonjac, M.Z. N-terminal pro-brain natriuretic peptide in the fetus. *Pediatr. Int.* 2014, 56, 373–377. [CrossRef]

52. Koch, L.; Dabeck, M.T.; Frommhold, D.; Poeschl, J. Stable precursor fragments of vasoactive peptides in umbilical cord blood of term and preterm infants. *Horm. Res. Paediatr.* 2011, 76, 234–239. [CrossRef] [PubMed]

53. Suga, S.; Nakao, K.; Hosoda, K.; Mukoyama, M.; Ogawa, Y.; Shirakami, G.; Arai, H.; Saito, Y.; Kambayashi, Y.; Inouye, K.; et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. *Endocrinology* 1992, 130, 229–239. [CrossRef]

54. Merz, W.M.; Leufgen, C.; Fimmers, R.; Stoffel-Wagner, B.; Gemburc, U. Reference intervals for N-terminal pro-B-type natriuretic peptide in amniotic fluid between 10 and 34 weeks of gestation. *PLoS ONE* 2014, 9, e114416. [CrossRef]

55. Carvajal, J.A.; Delpiano, A.M.; Cuello, M.A.; Sobrevia, L.A.; Weiner, C.P. Brain natriuretic peptide (BNP) produced by the human chorioamnion may mediate pregnancy myometrial quiescence. *Reprod. Sci.* 2009, 16, 32–42. [CrossRef]

56. Carvajal, J.A.; Ferrer, F.A.; Araya, F.I.; Delpiano, A.M. Normal amino-terminal pro-brain natriuretic peptide (NT-proBNP) values in amniotic fluid. *Clin. Biochem.* 2017, 50, 23–26. [CrossRef]

57. Miyoshi, T.; Hosoda, H.; Minamino, N. Significance of Atrial and Brain Natriuretic Peptide Measurements in Fetuses with Heart Failure. *Front. Physiol.* 2021, 12, 654356. [CrossRef] [PubMed]

58. Walthier, T.; Stepan, H.; Pankow, K.; Gembardt, F.; Faber, R.; Schultheiss, H.P.; Siems, W.E. Relation of ANP and BNP to their N-terminal fragments in fetal circulation: Evidence for enhanced neutral endopeptidase activity and resistance of BNP to neutral endopeptidase in the fetus. *BJOG 2004*, 111, 452–455. [CrossRef]

59. Suga, S.; Nakao, K.; Hosoda, K.; Mukoyama, M.; Ogawa, Y.; Shirakami, G.; Arai, H.; Saito, Y.; Kambayashi, Y.; Inouye, K.; et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. *Endocrinology* 1992, 130, 229–239. [CrossRef]

60. Merz, W.M.; Leufgen, C.; Fimmers, R.; Stoffel-Wagner, B.; Gemburc, U. Reference intervals for N-terminal pro-B-type natriuretic peptide in amniotic fluid between 10 and 34 weeks of gestation. *PloS ONE* 2014, 9, e114416. [CrossRef]
64. Kerkelä, R.; Ulvila, J.; Magga, J. Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events. *J. Am. Heart Assoc.* **2015**, *4*, e002423. [CrossRef]

65. Krüger, C.; Rauh, M.; Dörr, H.G. Immunoreactive renin concentrations in healthy children from birth to adolescence. *Clin. Chim. Acta* **1998**, *274*, 15–27. [CrossRef]

66. Albers, S.; Mir, T.S.; Haddad, M.; Läer, S. N-Terminal pro-brain natriuretic peptide: Normal ranges in the pediatric population including method comparison and interlaboratory variability. *Clin. Chem. Lab. Med.* **2006**, *44*, 80–85. [CrossRef]

67. Johns, M.C.; Stephenson, C. Amino-Terminal Pro–B-Type Natriuretic Peptide Testing in Neonatal and Pediatric Patients. *Am. J. Cardiol.* **2008**, *101*, S76–S81. [CrossRef]

68. O’Brien, F.; Walker, I.A. Fluid homeostasis in the neonate. *Paediatr. Anaesth.* **2014**, *24*, 49–59. [CrossRef]

69. Finnemore, A.; Groves, A. Physiology of the fetal and transitional circulation. *Semin. Fetal Neonatal Med.* **2015**, *20*, 210–216. [CrossRef]

70. Carbajal, R. Neonatal Pain. In *Emerging Topics and Controversies in Neonatology*; Boyle, E., Cusack, J., Eds.; Springer: Cham, Switzerland, 2020. [CrossRef]

71. Collin-Chavagnac, D.; Dehoux, M.; Schellenberg, E.; Cauliez, B.; Maupas-Schwalm, F.; Lefevre, G. Société Française de Biologie Cardiac Markers Working Group. Head-to-head comparison of 10 natriuretic peptide assays. *Clin. Chem. Lab. Med.* **2015**, *53*, 1825–1837. [CrossRef]

72. Miller, W.L.; Phelps, M.A.; Wood, C.M.; Schellenberger, U.; Van Le, A.; Perichon, R.; Jaffe, A.S. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. *Circ. Heart Fail* **2011**, *4*, 355–360. [CrossRef]

73. Prontera, C.; Zucchelli, G.C.; Vittorini, S.; Storti, S.; Emdin, M.; Clerico, A. Comparison between analytical performances of polyclonal and monoclonal electrochemiluminescence immunoassays for NTproBNP. *Clin. Chim. Acta* **2009**, *400*, 70–73. [CrossRef]